Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: two out of four closes were negative this week so far as the IBB closed up +0.30% and the XBI closed up +0.16%

November 21, 2019 6:26pm

While 6 out of the 19 upside had higher than the 3 month average volume while 12 out of the 21 downside had higher than the 3 month average volume

Finance: CRISPR Therapeutics (CRSP) priced its $247.5 M offering of 4.25 M shares at $64.50 per share with an additional 637. 5 K overallotment

Pre-open indications: 4 HITs

In the short run, values can be pretty senseless if one side or the other decides to be aggressive in their buying or selling.

Framing the main takeaway … pricing and volume creates volatility and liquidity!

The Dow closed DOWN -54.80 (-0.20%), the S&P closed DOWN -4.92 points (-0.16%) and the NASDAQ closed DOWN -20.52 points (-0.24%)

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

Thursday the IBB closed up +0.30% while the XBI closed up +0.16%
Wednesday the IBB closed up +0.51% while the XBI closed up +0.28%
Tuesday the IBB closed up +2.21% while the XBI closed up +2.18%
Monday the IBB closed down -0.26% while the XBI closed up +0.24%

The advance/decline line scenario of 45 covered companies:

Thursday the close was negative with an A/D line of 19/21, 2 flats, 1 reversed merged (HSGX) and 2 acquired;

Wednesday the close was positive with an A/D line of 23/18, 1 flat, 1 reversed merged (HSGX) and 2 acquired;

Tuesday the close was positive with an A/D line of 34/11, 1 flat, 1 reversed merged (HSGX) and 2 acquired;

Monday the close was negative with an A/D line of 18/22, 2 flats, 1 reversed merged (HSGX) and 2 acquired;

Henry’omics:

The sector got clipped to close down in tandem with the markets.

Indexes slipped on Thursday as investors digested the latest reports surrounding the U.S.-China trade war.

Thursday marked the third straight day of losses for the Dow, its longest losing streak since August. The S&P 500 posted its first three-day slide since September.

Theme of the week: When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started.

Decliners:

CRISPR Therapeutics (CRSP -$8.03 after an offering was proposed);
uniQure (QURE -$2.64 after Wednesday’s -$1.54);
Spark Therapeutics (ONCE -$0.45);
Vericel (VCEL -$0.40);
BioMarin Pharmaceuticals (BMRN -$0.36);

Incliners:

Alnylam Pharmaceuticals (ALNY +$2.99 after Wednesday’s +$7.34, Tuesday’s +$5.20, Monday’s +$0.68 and last Friday’s +$1.59);
ReNeuron (RENE.L +$1.50 after Wednesday’s -$4.00, Tuesday’s -$2.50 and Monday’s +$11.50);
BioLife Solutions (BLFS +$0.93);
Ionis Pharmaceuticals (IONS +$0.69 after Wednesday’s +$1.73);
Audentes Therapeutics (BOLD +$0.40);

The percentage (%) indicators:

Thursday’s range of the 19 upside was +0.10% (FATE) to +9.35% (SLDB) while the 21 downside ranged from -0.05% (RGNX) to -11.91% (CRSP);

Wednesday’s range of the 23 upside was +0.15% (ONCE) to +7.50% (ALNY) while the 18 downside ranged from -0.34% (BMRN) to -3.12% (EDIT);

Tuesday’s range of the 34 upside was +0.16% (ONCE) to +16.87% (CRSP) while the 7 downside ranged from -0.13% (AXGN) to -2.11% (CLBS);

Monday’s range of the 18 upside was +0.01% (BLUE) to +11.50% (RENE.L) while the 22 downside ranged from -0.23% (VYGR) to -4.75% (VSTM);

Upside volume stats: to compare

Thursday: 6 out of the 19 upside had higher than the 3 month average volume;
Wednesday: 10 out of the 23 upside had higher than the 3 month average volume;
Tuesday: 15 out of the 34 upside had higher than the 3 month average volume;
Monday: 8 out of the 18 upside had higher than the 3 month average volume;

Downside volume stats:

Thursday: 12 out of the 21 downside had higher than the 3 month average volume;
Wednesday: 4 out of the 18 downside had higher than the 3 month average volume;
Tuesday: 2 out of the 7 downside had higher than the 3 month average volume;
Monday: 5 out of the 22 downside had higher than the 3 month average volume;

2 flat – ADVM and PSTI with 1 reverse merged (HSGX), 2 acquired (AST & OSIR) and Spark Therapeutics’ (ONCE) acquisition by Roche could be soon according to rumors from FTC by year’s end.

November’s sessions:

Thursday closed NEGATIVE with 21 decliners, 19 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Wednesday closed POSITIVE with 18 decliners, 23 advancers, 1 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Tuesday closed POSITIVE with 7 decliners, 34 advancers, 1 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Monday closed NEGATIVE with 22 decliners, 18 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Friday closed POSITIVE with 13 decliners, 26 advancers, 3 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Thursday closed NEGATIVE with 25 decliners, 17 advancers, 0 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Wednesday closed NEGATIVE with 29 decliners, 12 advancers, 1 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Tuesday closed NEGATIVE with 29 decliners, 12 advancers, 1 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Monday closed NEGAIVE with 27 decliners, 14 advancers, 1 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Friday closed POSITIVE with 11 decliners, 29 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Thursday closed POSITIVE with 18 decliners, 21 advancers, 3 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Wednesday closed NEGATIVE with 27 decliners, 13 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Tuesday closed POSITIVE with 17 decliners, 23 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Monday closed NEGATIVE with19 decliners, 22 advancers, 1 flat and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Friday closed POSITIVE with 7 decliners, 33 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

8 hours 46 min ago
RegMed Investors’ (RMi) pre-open: head and knee down

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.